L’anticorps Humanized Monoclonal anti-CLDN18.2 (Zolbetuximab Biosimilar) a été validé pour FACS et in vivo. Il convient pour détecter CLDN18.2 (Zolbetuximab Biosimilar) dans des échantillons de Humain.
N° du produit ABIN7795131
Aperçu rapide pour Recombinant CLDN18.2 (Zolbetuximab Biosimilar) anticorps (ABIN7795131)
Antigène
CLDN18.2 (Zolbetuximab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Humanized
Clonalité
Monoclonal
Conjugué
Cet anticorp CLDN18.2 (Zolbetuximab Biosimilar) est non-conjugé
What is zolbetuximab biosimilar research grade? Zolbetuximab is a humanized monoclonal antibody directed against the human protein Claudin 18.2 (the isoform 2 of Claudin), and potentially used for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. Zolbetuximab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Zolbetuximab biosimilar uses the same protein sequences as the potential therapeutic antibody zolbetuximab . Claudin-18 in humans is a protein encoded by the CLDN18 gene. The CLDN18 protein belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. Isoform 2 (Claudin 18.2) is abundant in gastric tumors.